Neoplasia — MCQs
On this page
Which of the following is not an estrogen-dependent carcinoma?
What is the primary function of the p53 protein, often referred to as the 'guardian of the genome'?
Which tumor causes polycythemia due to erythropoietin production?
Which gene is commonly affected in breast cancer?
Which of the following is NOT a recognized use of tumor markers?
During a routine checkup, a 50-year-old man is found to have blood in his urine. He is otherwise in excellent health. An abdominal CT scan reveals a 2-cm right renal mass. You inform the patient that staging of this tumor is key to selecting treatment and evaluating prognosis. Which of the following is the most important staging factor for this patient?
The phenomenon of cancer cells switching to glycolysis even in the presence of adequate oxygen for oxidative phosphorylation is known as?
Tumour cells avoid immunogenic response by all except:
Which of the following disorders is least likely associated with progression to lymphoma?
Which of the following has the highest malignant transformation rate?
Neoplasia Indian Medical PG Practice Questions and MCQs
Question 11: Which of the following is not an estrogen-dependent carcinoma?
- A. Lobular carcinoma of the breast
- B. Follicular carcinoma of the thyroid (Correct Answer)
- C. Endometrial leiomyosarcoma
- D. Carcinoma of the prostate
Explanation: The correct answer is **B. Follicular carcinoma of the thyroid**. **1. Why Follicular Carcinoma of the Thyroid is the correct answer:** Follicular carcinoma of the thyroid is primarily driven by **TSH (Thyroid Stimulating Hormone)** levels and genetic mutations such as **RAS** or the **PAX8-PPARγ** rearrangement [1]. Unlike the other options, its pathogenesis and growth are not mediated by estrogen receptors (ER). While thyroid disorders are more common in females, the malignancy itself is not classified as an estrogen-dependent tumor [2]. **2. Analysis of Incorrect Options:** * **Lobular carcinoma of the breast:** This is a classic example of an estrogen-dependent tumor. Most invasive lobular carcinomas are **ER-positive** and respond well to hormonal therapies like Tamoxifen or Aromatase inhibitors. * **Endometrial leiomyosarcoma:** Uterine sarcomas and carcinomas are highly sensitive to the hormonal environment. Estrogen promotes the proliferation of the endometrial lining and myometrial cells; long-term unopposed estrogen is a significant risk factor for uterine malignancies. * **Carcinoma of the prostate:** While primarily androgen-dependent, the prostate gland is highly sensitive to the **estrogen-androgen balance**. Estrogens play a documented role in the development and progression of prostate cancer through ER-α and ER-β receptors. **3. NEET-PG High-Yield Pearls:** * **Estrogen-Dependent Tumors:** Include Breast (Ductal & Lobular), Endometrial, and Ovarian (Endometrioid/Serous) cancers. * **Thyroid Cancer Genetics:** * *Papillary:* BRAF mutations, RET/PTC rearrangements [3]. * *Follicular:* RAS mutations, PAX8-PPARγ translocation [1]. * *Medullary:* RET proto-oncogene (associated with MEN 2A/2B). * **Protective Factor:** Multiparity and oral contraceptives (OCPs) reduce the risk of ovarian and endometrial cancers by modulating estrogen exposure. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1100-1101. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 428-429. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1099-1100.
Question 12: What is the primary function of the p53 protein, often referred to as the 'guardian of the genome'?
- A. Increase in cell proliferation
- B. Evasion of apoptosis
- C. Induction of necrosis
- D. Reduction of cell mutation rate (Correct Answer)
Explanation: **Explanation:** The **p53 protein**, encoded by the *TP53* gene on chromosome 17p13.1, is the most commonly mutated gene in human cancers. It acts as a molecular "gatekeeper" that monitors cellular stress, particularly DNA damage [1]. **Why Option D is Correct:** When DNA damage is detected, p53 is activated and triggers three primary mechanisms [1]: 1. **Quiescence (Cell Cycle Arrest):** It induces p21, which inhibits Cyclin/CDK complexes, pausing the cell cycle at the G1-S checkpoint to allow time for DNA repair [1]. 2. **Senescence:** Permanent cell cycle arrest. 3. **Apoptosis:** If repair fails, p53 activates pro-apoptotic genes like *BAX* [1]. By ensuring that damaged DNA is either repaired or the cell is destroyed, p53 prevents the propagation of genetic errors, thereby **reducing the cell mutation rate** [2]. **Why Other Options are Incorrect:** * **Option A:** p53 *inhibits* cell proliferation; its loss or mutation leads to uncontrolled growth. * **Option B:** p53 *promotes* apoptosis in damaged cells. "Evasion of apoptosis" is a hallmark of cancer that occurs when p53 is inactivated. * **Option C:** p53 triggers programmed cell death (apoptosis), not necrosis (unregulated, inflammatory cell death). **NEET-PG High-Yield Pearls:** * **Li-Fraumeni Syndrome:** A germline mutation of *TP53* resulting in a high risk of diverse cancers (Sarcoma, Breast, Leukemia, Adrenal - "SBLA" syndrome). * **MDM2:** The primary negative regulator of p53; it targets p53 for degradation via the ubiquitin-proteasome pathway. * **HPV E6 Protein:** The Human Papillomavirus E6 oncoprotein binds to and degrades p53, leading to cervical cancer. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 302-304. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 226-227.
Question 13: Which tumor causes polycythemia due to erythropoietin production?
- A. Cerebellar hemangioma (Correct Answer)
- B. Medulloblastoma
- C. Ependymoma
- D. Oligodendroglioma
Explanation: **Explanation:** **Correct Answer: A. Cerebellar hemangioma** The association between certain tumors and polycythemia is due to **paraneoplastic syndrome**, where the tumor cells ectopically produce **Erythropoietin (EPO)**. [3] This stimulates the bone marrow to increase red blood cell production, leading to secondary polycythemia. **Cerebellar Hemangioblastoma** (often associated with Von Hippel-Lindau/VHL syndrome) is a classic producer of EPO. [1] Other high-yield tumors that cause this include: * **R**enal Cell Carcinoma (most common) * **H**epatocellular Carcinoma * **H**emangioblastoma * **U**terine Leiomyoma * **P**heochromocytoma *(Mnemonic: **R**eal **H**e-man **H**as **U**ltimate **P**ower)* **Why the other options are incorrect:** * **B. Medulloblastoma:** A highly malignant primitive neuroectodermal tumor (PNET) found in the cerebellum of children. [1] It does not have endocrine or EPO-secreting activity. * **C. Ependymoma:** Arises from the lining of the ventricles or central canal of the spinal cord. It typically presents with obstructive hydrocephalus, not paraneoplastic hematologic changes. * **D. Oligodendroglioma:** A slow-growing cortical tumor characterized by "fried-egg" appearance and "chicken-wire" capillaries. It is not associated with EPO production. **High-Yield Clinical Pearls for NEET-PG:** * **VHL Syndrome:** If a patient presents with a cerebellar hemangioblastoma, always screen for Renal Cell Carcinoma and Pheochromocytoma (VHL Gene on **Chromosome 3p**). [1] * **Polycythemia vs. Erythrocytosis:** In these tumors, only the RBC count is elevated (Secondary Erythrocytosis), unlike Polycythemia Vera where all three cell lines (RBCs, WBCs, Platelets) are typically increased. [2], [3] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 306-307. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 614-615. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 663-664.
Question 14: Which gene is commonly affected in breast cancer?
- A. WT1
- B. p53 (Correct Answer)
- C. RAS
- D. p83
Explanation: **Explanation:** **TP53 (p53)** is the most frequently mutated gene in human cancer, including breast cancer [1]. Known as the **"Guardian of the Genome,"** p53 is a tumor suppressor gene located on chromosome **17p13.1** [4]. It regulates the cell cycle by inducing G1-S arrest (via p21) [3] to allow for DNA repair or triggering apoptosis (via BAX) if damage is irreparable [2]. In breast cancer, p53 mutations are particularly prevalent in the "Triple Negative" and "HER2-enriched" subtypes. Germline mutations in p53 lead to **Li-Fraumeni Syndrome**, which carries a high risk of early-onset breast cancer [1]. **Analysis of Incorrect Options:** * **WT1 (Wilms Tumor 1):** This gene is located on chromosome 11p13. Mutations are characteristically associated with **Wilms Tumor (Nephroblastoma)** in children, not breast cancer. * **RAS:** While the RAS oncogene (especially KRAS) is the most common oncogene mutation in human cancers (highly prevalent in pancreatic and colon cancers), it is relatively **uncommon** in primary breast cancer compared to p53 or PIK3CA [2]. * **p83:** This is a distractor; it is not a recognized major tumor suppressor or oncogene associated with breast cancer pathogenesis in standard medical curricula. **High-Yield NEET-PG Pearls:** * **Most common mutation in breast cancer:** TP53 (overall), but **PIK3CA** is also highly frequent in Luminal A subtypes. * **BRCA1/BRCA2:** These are DNA repair genes (homologous recombination). BRCA1 is on chromosome **17**, and BRCA2 is on chromosome **13**. * **HER2/neu (ERBB2):** An amplifiable proto-oncogene located on chromosome **17q**. * **Li-Fraumeni Syndrome:** Remember the "SBLA" mnemonic (Sarcoma, Breast, Leukemia, Adrenal gland tumors). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, p. 1058. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 303-304. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 302-303. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 226-227.
Question 15: Which of the following is NOT a recognized use of tumor markers?
- A. Screening for cancer in asymptomatic individuals.
- B. Monitoring a cancer patient for recurrence.
- C. Confirming the diagnosis of a cancer. (Correct Answer)
- D. Assessing the response to treatment in a cancer patient.
Explanation: **Explanation:** The fundamental principle in oncology is that **tumor markers are never used to confirm a diagnosis of cancer.** The definitive diagnosis of malignancy always requires a histopathological examination (biopsy) or cytological study (FNAC). Tumor markers lack the necessary specificity and sensitivity for diagnosis because they can be elevated in non-neoplastic inflammatory conditions or may be absent in some patients with the disease [1]. **Analysis of Options:** * **Option C (Correct):** Tumor markers are biochemical indicators (hormones, enzymes, or proteins) that suggest the presence of a tumor but cannot prove it. For example, an elevated PSA can occur in benign prostatic hyperplasia (BPH), not just prostate cancer [1]. * **Option A:** While most markers are poor screening tools, a few are recognized for screening in high-risk populations (e.g., AFP for Hepatocellular Carcinoma in cirrhosis patients or PSA for prostate cancer) [1]. * **Option B:** This is the **most common** use of tumor markers. A rising level after surgery or chemotherapy is often the first sign of recurrence (e.g., rising CEA in colorectal cancer) [1], [2]. * **Option D:** Markers help assess if a tumor is shrinking. A rapid decline in levels post-therapy indicates a positive response to treatment [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Best Screening Marker:** PSA (Prostate Specific Antigen). * **Marker for Monitoring:** CEA (Carcinoembryonic Antigen) for colorectal cancer; CA-125 for ovarian cancer. * **Yolk Sac Tumor:** Alpha-fetoprotein (AFP) [1]. * **Choriocarcinoma:** beta-hCG. * **Medullary Carcinoma of Thyroid:** Calcitonin. * **Pancreatic Cancer:** CA 19-9. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 346. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 254-255.
Question 16: During a routine checkup, a 50-year-old man is found to have blood in his urine. He is otherwise in excellent health. An abdominal CT scan reveals a 2-cm right renal mass. You inform the patient that staging of this tumor is key to selecting treatment and evaluating prognosis. Which of the following is the most important staging factor for this patient?
- A. Histologic grade of the tumor
- B. Metastases to regional lymph nodes (Correct Answer)
- C. Proliferative capacity of the tumor cells
- D. Somatic mutations in the p53 tumor suppressor gene
Explanation: **Explanation:** In oncology, **Staging** (extent of spread) is almost always a more significant predictor of prognosis and treatment selection than **Grading** (degree of differentiation) [1]. **Why Option B is Correct:** The most widely used staging system is the **TNM system** (Tumor size, Node involvement, Metastasis) [1]. For most solid tumors, including Renal Cell Carcinoma (RCC), the presence of **regional lymph node metastases (N)** or distant metastases (M) signifies a higher stage and a significantly poorer prognosis compared to localized disease. Staging determines whether the tumor is resectable or requires systemic therapy. **Why Other Options are Incorrect:** * **Option A (Histologic Grade):** While the Fuhrman or ISUP grade (based on nuclear morphology) provides information about the tumor's aggressiveness, it is secondary to the anatomical stage in determining the overall clinical outcome. * **Option C (Proliferative Capacity):** Markers like Ki-67 indicate how fast cells are dividing. While useful in some cancers (like lymphomas), they are not the primary factor for staging or prognosis in RCC. * **Option D (p53 Mutations):** Molecular markers provide insights into pathogenesis and potential targeted therapies, but they do not replace the TNM staging system for prognostic evaluation. **NEET-PG High-Yield Pearls:** * **Staging vs. Grading:** Staging (TNM) is the **most important** prognostic factor for most solid tumors [1]. Grading is based on microscopic features (differentiation). * **RCC Classic Triad:** Hematuria, flank pain, and palpable mass (seen in only 10% of cases). * **RCC Spread:** Unique for its tendency to invade the **renal vein** and extend into the inferior vena cava (IVC) [2]. * **Most Common Subtype:** Clear cell carcinoma (associated with VHL gene deletion on chromosome 3p). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 236-237. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Kidney, pp. 959-961.
Question 17: The phenomenon of cancer cells switching to glycolysis even in the presence of adequate oxygen for oxidative phosphorylation is known as?
- A. Tyndall effect
- B. Warburg effect (Correct Answer)
- C. Hawthorne effect
- D. None of the above
Explanation: ### Explanation **Correct Answer: B. Warburg effect** The **Warburg effect** (aerobic glycolysis) is a hallmark of cancer metabolism [1]. Normally, differentiated cells use oxidative phosphorylation in the mitochondria to produce ATP when oxygen is available. However, cancer cells—even in oxygen-rich environments—reprogram their metabolism to favor **glycolysis** followed by lactic acid fermentation [2]. **Why do cancer cells do this?** While glycolysis is less efficient at producing ATP (2 ATP vs. 36 ATP per glucose molecule), it provides the rapidly dividing cell with metabolic intermediates (carbon skeletons) necessary for the synthesis of nucleic acids, proteins, and lipids required for new organelles [1], [2]. **Analysis of Incorrect Options:** * **A. Tyndall effect:** A physical phenomenon where light is scattered by particles in a colloid or a very fine suspension (e.g., visible dust in a sunbeam). It has no relevance to oncology. * **C. Hawthorne effect:** A psychological phenomenon where individuals modify their behavior because they are aware they are being observed. This is commonly discussed in Community Medicine/Biostatistics. **High-Yield Clinical Pearls for NEET-PG:** * **PET Scans (Positron Emission Tomography):** The Warburg effect is the clinical basis for PET imaging. Patients are injected with **18F-fluorodeoxyglucose (FDG)**, a glucose analog. Because tumor cells have high glucose uptake due to the Warburg effect, they appear as "hot spots" on the scan. * **Key Enzyme:** The switch is often mediated by the **PI3K/AKT signaling pathway** and the upregulation of **HIF-1̑** (Hypoxia-inducible factor), which increases the expression of glucose transporters (GLUT1) and glycolytic enzymes. * **Oncometabolites:** Mutations in enzymes like **Isocitrate Dehydrogenase (IDH)** can lead to the production of 2-hydroxyglutarate, which promotes epigenetic changes in cancer. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 308-310. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. With Illustrations By, pp. 26-27.
Question 18: Tumour cells avoid immunogenic response by all except:
- A. Decreased expression of MHC I molecule
- B. Decreased expression of MHC II molecule (Correct Answer)
- C. Immunosuppression
- D. Antigen loss
Explanation: **Explanation:** Tumor cells employ several mechanisms to evade the host immune system, a process known as "Immune Evasion." [2] **Why Option B is the correct answer:** MHC Class I molecules are expressed on all nucleated cells and are responsible for presenting intracellular (tumor) antigens to **CD8+ Cytotoxic T-cells**. [1] In contrast, **MHC Class II** molecules are primarily expressed on professional Antigen-Presenting Cells (APCs) like macrophages and B-cells to activate CD4+ Helper T-cells. [1], [3] Since tumor cells are not professional APCs, the "decreased expression of MHC II" is not a primary or standard mechanism used by the tumor cell itself to avoid direct recognition. **Analysis of Incorrect Options:** * **A. Decreased expression of MHC I:** This is a classic evasion tactic. By downregulating MHC I, tumor cells become "invisible" to CD8+ T-cells, which require MHC I to recognize and kill mutated cells. [2] * **C. Immunosuppression:** Tumors create an immunosuppressive microenvironment by secreting cytokines like **TGF-β** and **IL-10**, or by recruiting **Regulatory T-cells (Tregs)** and Myeloid-derived suppressor cells (MDSCs) which inhibit the anti-tumor immune response. [4], [5] * **D. Antigen loss:** Through "immunoediting," highly immunogenic clones are eliminated by the immune system, leaving behind "antigen-negative" variants that the immune system can no longer detect. [2] **NEET-PG High-Yield Pearls:** * **PD-L1 Expression:** Tumors often express PD-L1, which binds to PD-1 on T-cells, leading to T-cell exhaustion (a target for Checkpoint Inhibitor therapy). * **NK Cell Role:** While low MHC I helps evade T-cells, it should theoretically trigger **Natural Killer (NK) cells**. However, tumors often evolve to also inhibit NK cell activating receptors. [5] * **TGF-β:** Known as the most potent immunosuppressive cytokine produced by tumors. [4] **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 156-157. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 318-319. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, p. 240. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 317-318. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 320-322.
Question 19: Which of the following disorders is least likely associated with progression to lymphoma?
- A. Sjogren's syndrome
- B. Ataxia telangiectasia
- C. Severe combined immunodeficiency (Correct Answer)
- D. Lynch II syndrome
Explanation: ### Explanation The association between immunodeficiency/autoimmunity and lymphoma is a high-yield concept in NEET-PG pathology. **Why Option C is the Correct Answer:** While it seems counterintuitive, **Severe Combined Immunodeficiency (SCID)** is the least likely among these options to progress to lymphoma. This is because SCID involves a profound defect in both T-cell and B-cell lineages. Lymphomagenesis typically requires a "proliferative drive" or a population of dysfunctional lymphocytes that can undergo malignant transformation. In SCID, the absolute lack of functional lymphoid precursors means there is no substrate for lymphoma to develop; patients usually succumb to opportunistic infections in early infancy before any neoplastic transformation can occur [1]. **Analysis of Incorrect Options:** * **Sjogren’s Syndrome:** This autoimmune condition carries the highest risk of lymphoma among all autoimmune diseases (approx. 40-fold increase), typically resulting in **MALToma** or Diffuse Large B-Cell Lymphoma (DLBCL) due to chronic B-cell stimulation [2]. * **Ataxia Telangiectasia:** This is a DNA repair defect (ATM gene). The inability to repair double-strand breaks leads to genomic instability, making these patients highly susceptible to lymphoid malignancies (T-cell leukemias and lymphomas) [3]. * **Lynch II Syndrome:** Also known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC) plus extra-colonic tumors. While primarily associated with GI and endometrial cancers, Lynch II is associated with an increased risk of various hematological malignancies, including non-Hodgkin lymphoma, due to mismatch repair (MMR) defects. **NEET-PG High-Yield Pearls:** * **Highest risk of Lymphoma:** Sjogren’s Syndrome (MALToma of the parotid gland) [2]. * **Wiskott-Aldrich Syndrome:** Another immunodeficiency with a very high risk of B-cell lymphoma (often EBV-associated) [3]. * **Hashimoto Thyroiditis:** Associated with Thyroid B-cell lymphoma [2]. * **Celiac Disease:** Associated with Enteropathy-associated T-cell lymphoma (EATL). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 167-168. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 235-236. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 250-251.
Question 20: Which of the following has the highest malignant transformation rate?
- A. Erythroplakia
- B. Proliferative verrucous leukoplakia (Correct Answer)
- C. Speckled leukoplakia
- D. Homogenous leukoplakia
Explanation: **Explanation:** The risk of malignant transformation in oral potentially malignant disorders (OPMDs) depends on the clinical subtype, degree of dysplasia, and growth pattern. **Why Proliferative Verrucous Leukoplakia (PVL) is correct:** PVL is a rare, aggressive form of leukoplakia characterized by a multifocal, persistent, and exophytic growth pattern. It is notoriously resistant to treatment and has the **highest malignant transformation rate (often >70-90%)**. Unlike other forms, it frequently progresses to Verrucous Carcinoma or Squamous Cell Carcinoma (SCC) over time, making it the most dangerous clinical variant. **Analysis of Incorrect Options:** * **Erythroplakia:** While a single lesion of erythroplakia has a higher risk of malignancy (approx. 50%) than a single lesion of *standard* leukoplakia, it is surpassed by the aggressive, progressive nature of PVL. * **Speckled Leukoplakia (Erythroleukoplakia):** This is a mixed red-and-white lesion. It carries a higher risk than homogenous leukoplakia but lower than PVL or pure erythroplakia. * **Homogenous Leukoplakia:** This is the most common clinical type but has the **lowest** malignant transformation rate (approx. 1-5%) [1]. It appears as a uniform flat, white plaque. **High-Yield Clinical Pearls for NEET-PG:** * **Hierarchy of Risk:** PVL > Erythroplakia > Speckled Leukoplakia > Homogenous Leukoplakia. * **Site Risk:** Leukoplakia on the **floor of the mouth, lateral tongue, and soft palate** carries the highest risk of malignancy. * **Gender:** PVL shows a strong predilection for **elderly females** and is often *not* associated with tobacco use, unlike other leukoplakias. * **Histology:** The presence of **epithelial dysplasia** is the most important histological predictor of malignant transformation [1], [2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Alimentary System Disease, pp. 344-345. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, pp. 737-741.
Practice by Chapter
Nomenclature and Classification of Tumors
Practice Questions
Characteristics of Benign and Malignant Neoplasms
Practice Questions
Molecular Basis of Cancer
Practice Questions
Carcinogenesis and Carcinogens
Practice Questions
Tumor Progression and Metastasis
Practice Questions
Tumor Markers
Practice Questions
Paraneoplastic Syndromes
Practice Questions
Genetic Basis of Cancer
Practice Questions
Tumor Immunity
Practice Questions
Cancer Epidemiology and Prevention
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free